Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gennex LaboratoriesBOM:531739 -2.48%81 Gross Margin % is 13.67% as of Mar. 2026, which is 63% below its 10-year median of 36.76. GuruFocus rates BOM:531739 with a GF Score™ of 81/100 and a GF Value™ of ₹15.50 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 943 Drug Manufacturers companies, Gennex Laboratories ranks worse than 86.21% on this metric.
Gennex Laboratories Ltd gross margin has been in long-term decline. The average rate of decline per year is -7.4%.
The historical rank and industry rank for Gennex Laboratories's Gross Margin % or its related term are showing as below:
BOM:531739'
s Gross Margin % Range Over the Past 10 Years
Min: 25.6 Med: 36.76 Max: 40.92
Current: 25.6
During the past 13 years, the highestGross Margin % of Gennex Laboratories was 40.92%. The lowest was 25.60%. And the median was 36.76%.
BOM:531739's Gross Margin % is ranked worse than 86.21% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:531739: 25.60
Gennex Laboratories had a gross margin of 13.67% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Gennex Laboratories was -7.40% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Gennex Laboratories had a gross margin of 13.67% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Gennex Laboratories Gross Margin % Related Terms
Gennex Laboratories Gross Margin % Historical Data
* Premium members only.
The historical data trend for Gennex Laboratories's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531739 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gennex Laboratories's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gennex Laboratories Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gennex Laboratories's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Gennex Laboratories's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Gennex Laboratories (BOM:531739) has a Gross Margin % of 13.67% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Gennex Laboratories and its competitors. This is 63% below median its historical median of 36.76. Over the past decade, Gennex Laboratories' Gross Margin % has ranged from 25.60 to 40.92. According to the industry distribution chart, Gennex Laboratories ranks #813 out of 943 companies in the Drug Manufacturers industry, placing it in the top 86.2%.
Is Gennex Laboratories' Gross Margin % too high?
Gennex Laboratories' current Gross Margin % of 13.67% is 63% below median its 10-year median of 36.76. Over the past 10 years, this metric has ranged from a low of 25.60 to a high of 40.92. The Drug Manufacturers industry median Gross Margin % is 48.54. Gennex Laboratories' value of 13.67% is 71.8% below this industry median. Based on the distribution chart, Gennex Laboratories ranks #813 out of 943 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gennex Laboratories has a GF Score™ of 81/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gennex Laboratories' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gennex Laboratories ranks #813 out of 943 companies for Gross Margin %. This places Gennex Laboratories in the lower half of its industry. The industry median Gross Margin % is 48.54. Gennex Laboratories' value of 13.67% is 71.8% below this benchmark. Historically, Gennex Laboratories' own Gross Margin % has ranged from 25.60 to 40.92 over the past decade. While the company's 10-year median is 36.76 vs. the industry median of 48.54, Gennex Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gennex Laboratories's current Gross Margin % of 13.67% is 71.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Gennex Laboratories and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gennex Laboratories's current Gross Margin % is 13.67%, which is 63% below median its own 10-year median of 36.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gennex Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Gennex Laboratories (BOM:531739) is currently considered Possible Value Trap. The stock's GF Value™ is ₹15.50, compared to a current price of ₹9.05 — trading 41.6% below its estimated fair value. The current Gross Margin % is 13.67%, which is 63% below median its 10-year median of 36.76 and 71.8% below the Drug Manufacturers industry median of 48.54. Gennex Laboratories' overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Gennex Laboratories (BOM:531739), the current Gross Margin % is 13.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gennex Laboratories (BOM:531739) Overvalued in 2026?
Based on GuruFocus' analysis, Gennex Laboratories stock appears to be undervalued.
The current stock price of ₹9.05 is trading 41.6% below its estimated GF Value™ of ₹15.50.
GuruFocus considers Gennex Laboratories to be Possible Value Trap.
Key valuation signals for BOM:531739:
Gross Margin %: 13.67% (63% below median its 10-year median of 36.76)
GF Value™: ₹15.50 vs. price of ₹9.05 (41.6% below fair value)
Industry Position: 71.8% below the Drug Manufacturers median (#813 of 943)
No single metric tells the full story. See the BOM:531739 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gennex Laboratories Ltd is engaged in the manufacturing of bulk drugs, and intermediates, Biotech Products. Geographically, the group has a business presence in Bangladesh, Egypt, Germany, Guatemala, Iran, Israel and other countries. Its products include Guaifenesin, Methocarbamol, Fluconazole and Phenazopyridine, among others.
81GF Score
Get the complete analysis for BOM:531739
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531739 has been successfully added to your 
